CDK4 and melanoma: To determine the expression of KGA, GAC and GLS2 in senescent cells induced by prolonged treatment of CDK4/6i, we treated a variety of melanoma cell lines harboring different oncogenic drivers (BrafWTNrasWT, BrafV600ENrasWT (BrafV600E) and BrafWTNrasQ61R/K (NrasQ61)) with CDK4/6i palbociclib for 8 days, compared to normal human melanocyte (ATCC-HEMa) as a control.